摘要
近年来,多发性骨髓瘤的诊断及治疗、疗效评估均进展迅速,新药包括新的蛋白酶体抑制剂、新的免疫调节剂、单克隆抗体以及细胞免疫治疗的出现带来了诊断标准、诊断手段以及疗效评价标准的不断更新。就目前的诊治新进展进行综述,以期指导临床。
The diagnosis, treatment and efficacy evaluation of multiple myeloma are progressing rapidly in recent years. Novel agents including new proteasome inhibitors, new immunomodulators, monoclonal antibodies and cellular therapy have non-stoppingly updated the diagnostic criteria, diagnostic methods and evaluation criteria. This article reviews the current progress in diagnosis and treatment of multiple myeloma in order to guide clinical practice.
作者
路瑾
LU Jin(Peking University People's Hospital,Institute of Hematology of Peking University,Collaborative Innovation Center of Hematology,Beijing 100044,China)
出处
《山东大学学报（医学版）》
CAS
北大核心
2019年第7期40-43,54,共5页
Journal of Shandong University:Health Sciences
基金
北京大学医学部-密歇根大学医学部转化医学与临床研究联合项目(BMU20160562)
关键词
多发性骨髓瘤
诊断标准
疗效评价标准
治疗
Multiple myeloma
Diagnostic criteria
Evaluation criteria
Treatment
